Ultivue
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Ultivue's InSituPlex® technology eliminates the need for assay development and enables scientists to unmask and analyze the true biological context of tissue samples. With the ability to run a same-slide fluorescent and H&E stain, Ultivue's technology is enabling pathologists to connect traditional morphological analysis with multiplexed immunofluorescent data for comprehensive single-cell phenotyping.
-
SEP 12, 2023 | 9:00 AM
In recent years, significant progress has been made in tissue-based technology, opening up unparalleled opportunities for identifying disease process biomarkers and gaining invaluable insigh... -
JAN 18, 2023 | 8:00 AM
Date: January 18, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomark...
-
OCT 26, 2022 | 8:00 AM
Date: October 26, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the pa...
-
MAY 26, 2021 | 9:00 AM
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
-
APR 16, 2020 | 9:00 AM
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
-
MAR 21, 2019 | 7:00 AM
DATE: March 21, 2019TIME: 7:00am PDT, 10:00am EDT The benefits of multiplex immunohistochemistry assays for tissue analysis are numerous. High-level multipl...
-
APR 30, 2024Immuno-Oncology Virtual Event Series 2024
-
MAY 07, 20243rd International Biosecurity Virtual Symposium
-
JUN 06, 2024The Future of Scientific Conferencing
- See More
-
MAY 07, 2024Is It Anti-RNP or Anti-Sm/RNP?
- See More
